Volume 27, Issue 3 (Iran South Med J 2025)
Iran South Med J 2025, 27(3): 205-214 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Derakhshan S, Moassesghafari B, Rhmani K. Evaluation of heart rate and pulmonary uptake in dipyridamole myocardial perfusion imaging in patients with suspected coronary artery disease and their relationship with clinical risk factors. Iran South Med J 2025; 27 (3) :205-214
URL: http://ismj.bpums.ac.ir/article-1-2055-en.html
URL: http://ismj.bpums.ac.ir/article-1-2055-en.html
1- Department of Radiotherapy, School of Paramedical Medicine, Kurdistan University of Medical Scienc-es, Sanandaj, Iran , siamakderakhshan@yahoo.com
2- Department of Radiology, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
3- Department of community medicine, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj
2- Department of Radiology, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
3- Department of community medicine, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj
Abstract: (738 Views)
Background: Non-imaging findings in myocardial perfusion imaging (MPI) may be helpful in patients with suspected coronary artery disease (CAD). The aim of this study was to investigate heart rate and pulmonary uptake and their relationship with clinical risk factors in these patients.
Materials and Methods: A total of 354 non-smokers (98 men and 256 women) with suspected CAD and no history of lung disease who were referred to Kowsar Nuclear Medicine Center in Sanandaj in 2022 for MPI with dipyridamole were examined. Resting heart rate (RHR), peak heart rate after dipyridamole injection (PHR) and lung-to-heart ratio (LHR) in the stress phase were measured and their relationship with age, gender, BMI, diabetes, hypertension and hyperlipidemia was evaluated in two groups –those with normal and those with abnormal scans.
Results: Patients with diabetes or hypertension had a significantly higher RHR compared to the non-diabetes non-hypertension cases. PHR had a significant relationship only with age and gender (P<0.0001). In the multivariate regression analysis, a significant correlation was observed between LHR and abnormal scan (P=0.03) and male gender (P=0.01).
Conclusion: Although diabetes and hypertension increased RHR, the only factors affecting PHR were age and gender, so that the lowest heart rate response to dipyridamole was observed in older adults and men. In addition to an abnormal scan, male gender also increased the likelihood of an abnormal LHR.
Materials and Methods: A total of 354 non-smokers (98 men and 256 women) with suspected CAD and no history of lung disease who were referred to Kowsar Nuclear Medicine Center in Sanandaj in 2022 for MPI with dipyridamole were examined. Resting heart rate (RHR), peak heart rate after dipyridamole injection (PHR) and lung-to-heart ratio (LHR) in the stress phase were measured and their relationship with age, gender, BMI, diabetes, hypertension and hyperlipidemia was evaluated in two groups –those with normal and those with abnormal scans.
Results: Patients with diabetes or hypertension had a significantly higher RHR compared to the non-diabetes non-hypertension cases. PHR had a significant relationship only with age and gender (P<0.0001). In the multivariate regression analysis, a significant correlation was observed between LHR and abnormal scan (P=0.03) and male gender (P=0.01).
Conclusion: Although diabetes and hypertension increased RHR, the only factors affecting PHR were age and gender, so that the lowest heart rate response to dipyridamole was observed in older adults and men. In addition to an abnormal scan, male gender also increased the likelihood of an abnormal LHR.
Type of Study: Original |
Subject:
nuclear medicine
Received: 2024/09/14 | Accepted: 2024/11/20 | Published: 2025/01/25
Received: 2024/09/14 | Accepted: 2024/11/20 | Published: 2025/01/25
References
1. Hasani WSR, Muhamad NA, Hanis TM & et al. The global estimate of premature cardiovascular mortality: a systematic review and meta-analysis of age-standardized mortality rate. BMC Public Health 2023; 16; 23(1): 1561. [DOI]
2. Srikanthan P, Horwich TB, Calfon Press M & et al. Sex Differences in the Association of Body Composition and Cardiovascular Mortality. J Am Heart Assoc 2021; 10(5): e017511. [DOI]
3. Bashar H, Kobo O, Khunti K & et al. Impact of Social Vulnerability on Diabetes-Related Cardiovascular Mortality in the United States. J Am Heart Assoc 2023; 12(21): e029649. [DOI]
4. Heo R, Nakazato R, Kalra D & et al. Noninvasive imaging in coronary artery disease. Semin Nucl Med 2014; 44(5): 398-409. [DOI]
5. Henzlova MJ, Duvall WL, Einstein AJ & et al. ASNC Imaging Guidelines for SPECT Nuclear Cardiology Procedures: Stress, Protocols, and Tracers. J Nucl Cardiol 2016; 23(3): 606-639. [DOI]
6. Hellsten Y, Nyberg M, Jensen LG & et al. Vasodilator interactions in skeletal muscle blood flow regulation. J Physiol 2012; 590(24): 6297-305. [DOI]
7. Leppo JA. Dipyridamole myocardial perfusion imaging. J Nucl Med 1994; 35(4): 730-3. [Article]
8. AlJaroudi W, Campagnoli T, Fughhi I & et al. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease. J Nucl Cardiol 2016; 23(3): 560-9. [DOI]
9. Abidov A, Hachamovitch R, Hayes SW & et al. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation 2003; 107(23): 2894-9. [DOI]
10. Hage FG, Dean P, Iqbal F & et al. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2011; 18(6): 1086-94. [DOI]
11. Aaty A, Al Fattah AA, Allam AH. Each Nuclear Cardiology lab should have its own lower limit of normal for functional parameters: True or False?. J Nucl Cardiol 2018; 25(2): 661–664. [DOI]
12. Cortigiani L, Carpeggiani C, Meola L & et al. Reduced Sympathetic Reserve Detectable by Heart Rate Response after Dipyridamole in Anginal Patients with Normal Coronary Arteries. J Clin Med 2022; 11(1): 52. [DOI]
13. Bhatheja R, Francis GS, Pothier CE & et al. Heart Rate Response during Dipyridamole Stress as a Predictor of Mortality in Patients with Normal Myocardial Perfusion and Normal Electrocardiograms. Am J Cardiol 2005; 95(10): 1159-64. [DOI]
14. Gebhard C, Messerli M, Lohmann C & et al. Sex and age differences in the association of heart rate responses to adenosine and myocardial ischemia in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2020; 27(1): 159-70. [DOI]
15. Maleki F, Ghaedian T. Correlation of heart rate response to dipyridamole stress during SPECT myocardial perfusion imaging with clinical factors. Iranian Journal of Nuclear Medicine 2024; 32(1): 33-39. [DOI]
16. Choi S, Baudot M, Vivas O & et al. Slowing down as we age: aging of the cardiac pacemaker’s neural control. GeroScience 2022; 44(1): 1–17. [DOI]
17. Nappi C, Assante R, Zampella E & et al. Relationship between heart rate response and cardiac innervation in patients with suspected or known coronary artery disease. J Nucl Cardiol 2021; 28(6): 2676-83. [DOI]
18. Kamal A, Hassan E, Azab S & et al. Reduced Heart Rate Response during Drug-Induced Stress Is Related to the Severity of Perfusion Defect. WJCD 2021; 11(11): 539- 51. [DOI]
19. Aaty AA, El-DeenZaky AT, Lotfy MI & et al. Heart Rate Response to Dypiridamole Stress in Relation to Perfusion and Function during Gated Technecium Tc99 M Sestamibi SPECT Study. JCCR 2015; 2(3): 00063. [DOI]
20. Palatini P. Resting heart rate as a cardiovascular risk factor in hypertensive patients: an update. Am J Hypertens 2021; 34(4): 307–17. [DOI]
21. Omlor AJ, Trudzinski FC, Alqudrah M & et al. Time-updated resting heart rate predicts mortality in patients with COPD. Clin Res Cardiol 2020; 109(6): 776–86. [DOI]
22. Kamimura D, Tamura K. Resting heart rate as a possible biomarker and target to prevent future cardiovascular disease in type 2 diabetes patients (HTR-2023-0066.R2). Hypertens Res 2023; 46(5): 1160- 1162. [DOI]
23. Ghaedian T, Mirzaei M, Ghaedian MM. Relationship between Baseline ECG Abnormalities and Quantitative Perfusion Parameters of Myocardial Perfusion Findings. Iran South Med J 2020; 22(6): 381-91. [Article]
24. Bajaj NS, Singh S, Farag A & et al. The prognostic value of non-perfusion variables obtained during vasodilator stress myocardial perfusion imaging. J. Nucl Cardiol 2016; 23(3): 390-413. [DOI]
25. Katsikis A, Theodorakos A, Papaioannou S & et al. Adenosine stress myocardial perfusion imaging in octogenarians: Safety, tolerability, and long-term prognostic implications of hemodynamic response and SPECTrelated variables 2019; J Nucl Cardiol 26(1): 250-62. [DOI]
26. Bian J, Herzog CA, Rangaswami J & et al. Lung sestamibi uptake on myocardial perfusion imaging and outcomes in chronic kidney disease. Cardiorenal Medicine 2021; 11(1): 67-76. [DOI]
27. Xu J, Cai F, Geng C & et al. Diagnostic Performance of CMR, SPECT, and PET Imaging for the Identification of Coronary Artery Disease: A Meta-Analysis. Front Cardiovasc Med 2021; 8: 621389. [DOI]
28. Patel M, Bui L, Kirkeeide R. et al. Imaging Microvascular Dysfunction and Mechanisms for Female-Male Differences in CAD. JACC Cardiovasc Imaging 2016; 9(4): 465-82. [DOI]
29. Imoto A, Tateishi E, Murakawa K & et al. Lung-to-heart ratio analysis using virtual planar images obtained from myocardial perfusion SPECT data: A phantom and clinical studies. J Nucl Cardiol 2023; 30(5): 1959-67. [DOI]
30. Erol M, Tezcan H, Duran M & et al. The role of myocardial perfusion imaging in predicting myocardial ischemia in patients diagnosed with long COVID. Int J Cardiovasc Imaging 2023; 39(11): 2279-84. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
